Market Newsdesk

LEHI, Utah, Nov. 20, 2020 /PRNewswire/ — Purple Innovation, Inc. (NASDAQ: PRPL) (“the Company”), the leader in comfort innovation and the creator of the renowned Purple® Mattress, announced today that as of November 19, 2020, approximately 9,828,000 Public Warrants and all of the Incremental Loan Warrants had been exercised since October 27, 2020.

As previously announced, on October 27, 2020, the Company provided notice to the holders of the Public Warrants and the Incremental Loan Warrants that their warrants will be redeemed in accordance with the terms of such warrants on November 30, 2020.

As a courtesy, the Company would like to remind any remaining holders of Public Warrants that if the remaining approximately  1,229,000 Public Warrants are not exercised prior to November 30, 2020, they will be redeemed on that date at the redemption price of $0.01 per warrant.

Questions concerning redemption and exercise of such public warrants can be directed to Philadelphia Stock Transfer at [email protected] or (866) 223-0448.

About Purple

Purple is a digitally-native vertical brand with a mission to help people feel and live better through innovative comfort solutions. We design and manufacture a variety of innovative, premium, branded comfort products, including mattresses, pillows, cushions, frames, sheets and more. Our products are the result of over 25 years of innovation and investment in proprietary and patented comfort technologies and the development of our own manufacturing processes. Our proprietary gel technology, Hyper-Elastic Polymer®, underpins many of our comfort products and provides a range of benefits that differentiate our offerings from other competitors’ products. We market and sell our products through our direct-to-consumer online channels, traditional retail partners, third-party online retailers and our owned retail showrooms. For more information on Purple, visit purple.com.

Investor Contact:

Brendon Frey, ICR
[email protected] 
203-682-8200

Purple Innovation, Inc.

Misty Bond

Director of Purple Communications
[email protected] 
385-498-1851

View original content to download multimedia:http://www.prnewswire.com/news-releases/purple-innovation-redemption-of-public-warrants-reminder-301177964.html

SOURCE Purple Innovation, Inc.

SAN DIEGO, Nov. 20, 2020 /PRNewswire/ — Biocept, Inc. (Nasdaq: BIOC), a leading commercial provider of molecular diagnostic assays, products and services designed to provide physicians with clinically actionable information to improve patient outcomes, announces the results of a study analyzing cerebrospinal fluid (CSF) samples in patients with primary lung or breast cancer with either brain or leptomeningeal disease.  The findings indicate that Target Selector™ CSF assays are a viable and sensitive platform for circulating tumor cell (CTC) detection and molecular analysis compared to the current standard of care, CSF cytology, which is typically used to establish or confirm leptomeningeal disease when imaging findings are suspicious or equivocal.  CSF cytology has limited sensitivity and provides no additional information needed for target therapy choice.  

The results were discussed yesterday in a poster presentation by Santosh Kesari, MD, PhD, Chair and Professor, Department of Translational Neurosciences, Director of Neuro-oncology at the Pacific Neuroscience Institute and John Wayne Cancer Institute, at the Society for Neuro-Oncology’s SNO2020 Virtual Conference on November 19, 2020.

“Once a tumor has metastasized to the brain, CTCs and circulating tumor DNA (ctDNA) can be found in the cerebrospinal fluid,” said Dr. Kesari.  “This prospective study compared the sensitivity of CTC detection and molecular analysis of Biocept’s Target Selector™ CSF assays to cytology (microscopic examination of conventional CSF cytology slide preps).  This study highlights the potential of CSF-based diagnostics for longitudinal monitoring cancers in the central nervous system.”

“Our Target Selector™ testing is a minimally invasive, cost-effective strategy to simultaneously confirm metastasis to the brain, while also assessing cancer biomarkers in order to qualify a patient for potential targeted therapy  options,” said Michael Nall, President and CEO of Biocept.  “Identifying CTCs and actionable biomarkers with Target Selector™ can help to confirm and monitor central nervous system involvement when clinically suspected, without the risk of complications associated with surgical biopsies, which are often impossible in these cases.  

“This the second major scientific conference in less than two months to accept study results from Target Selector™ testing in cerebrospinal fluid for presentation,” added Mr. Nall.  “We view neuro-oncology as an area where our technology is uniquely suited to answer questions posed by treating physicians, and we are appreciative of the Society of Neuro-Oncology’s recognition of our Target Selector™ testing.”

About the SNO2020 Virtual Conference

The Society for Neuro-Oncology exists to advance multi-disciplinary brain tumor research, education, and collaboration to drive discovery and improve patient care.  Over 2,600 neuro-oncology professionals are expected to register for the SNO2020 Virtual Conference being held November 19-21, 2020.  More information can be found at soc-neuro-onc.org.

About Biocept

Biocept, Inc. is a molecular diagnostics company with commercialized assays for lung, breast, gastric, colorectal and prostate cancers, and melanoma. The Company uses its proprietary liquid biopsy technology to provide physicians with clinically actionable information for treating and monitoring patients diagnosed with cancer. The Company’s patented Target Selector™ liquid biopsy technology platform captures and analyzes tumor-associated molecular markers in both circulating tumor cells (CTCs) and in circulating tumor DNA (ctDNA). With thousands of tests performed, the platform has demonstrated the ability to identify cancer mutations and alterations to inform physicians about a patient’s disease and therapeutic options. Additionally, Biocept is offering nationwide COVID-19 polymerase chain reaction (PCR) testing to support public health efforts during this unprecedented pandemic. For more information, please visit www.biocept.com.

Forward-Looking Statements Disclaimer Statement
This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like “may,” “will,” “should,” “could,” “expect,” “anticipate,” “estimate,” “believe,” “intend,” or “project” or the negative of these words or other variations on these words or comparable terminology. To the extent that statements in this release are not strictly historical, including without limitation statements regarding neuro-oncology being an area where Biocept’s technology is uniquely suited to answer questions posed by treating physiciansthe ability of Biocept’s platform to identify cancer mutations and alterations to inform physicians about a patient’s disease and therapeutic options, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous risk factors as set forth in our Securities and Exchange Commission (SEC) filings. The effects of such risks and uncertainties could cause actual results to differ materially from the forward-looking statements contained in this release. We do not plan to update any such forward-looking statements and expressly disclaim any duty to update the information contained in this press release except as required by law. Readers are advised to review our filings with the SEC, which can be accessed over the Internet at the SEC’s website located at www.sec.gov.

Investor Contact

:
 

LHA Investor Relations

Jody Cain

[email protected] 
310-691-7100

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/study-shows-biocepts-assays-are-viable-and-sensitive-for-detecting-tumor-cells-and-biomarkers-in-the-cerebrospinal-fluid-of-patients-with-breast-and-lung-cancer-that-has-metastasized-to-the-central-nervous-system-301177929.html

SOURCE Biocept, Inc.

PHOENIX, Nov. 20, 2020 /PRNewswire/ — Harvest Health & Recreation Inc. (“Harvest”) (CSE: HARV, OTCQX: HRVSF), a vertically integrated cannabis company and multi-state operator in the U.S., is pleased to announce the settlement of its dispute with a small group of the previous owners of Interurban Capital Group (“ICG”).

On March 13, 2020, Harvest completed a merger with Interurban Capital Group, LLC for approximately US$85.8 million payable by issuance of 309,452 of Harvest’s Multiple Voting Shares, assumption of approximately $19.1 million of debt convertible into 205,594 Multiple Voting Shares and payment of an additional $9.3 million upon exercise of a call option agreement to acquire controlling interests in five Washington cannabis dispensaries or alternatively $12.4 million to acquire substantially all of the assets of these dispensaries. On April 3, 2020, Harvest commenced litigation proceedings against the Washington dispensaries and a small group of the previous owners of ICG to enforce terms of service agreements and the call option agreements.

Settlement talks resulted in a mutually agreeable resolution for all parties. In accordance with the terms of a binding settlement agreement, Harvest will cancel a total of 42,378.4 Multiple Voting Shares issued to the small group of previous owners of ICG (equivalent to 4,237,840 Subordinate Voting Shares on an as-converted basis). Harvest will also receive a $12 million secured promissory note with 7.5% interest and five-year maturity. The settlement includes cancellation of the service agreements and call option agreements for the Washington retail locations. The settlement agreement is subject to the parties entering into definitive agreements as set forth in the settlement agreement and applicable state regulatory approval.

“We are pleased to settle this dispute and move forward,” said Chief Executive Officer Steve White. “We are very excited to continue to focus on our core business operations as we execute on our plan to return to profitability.”

About Harvest Health & Recreation Inc.

Headquartered in Tempe, Arizona, Harvest Health & Recreation Inc. is a vertically integrated cannabis company and multi-state operator. Since 2011, Harvest has been committed to expanding its retail and wholesale presence throughout the U.S., acquiring, manufacturing, and selling cannabis products for patients and consumers in addition to providing services to retail dispensaries. Through organic license wins, service agreements, and targeted acquisitions, Harvest has assembled an operational footprint spanning multiple states in the U.S. Harvest’s mission is to improve lives through the goodness of cannabis. We hope you’ll join us on our journey:


https://harvesthoc.com


 

Facebook: 

@HarvestHOC


Instagram: 

@HarvestHOC


Twitter: 

@HarvestHOC

Forward-looking Statements

This press release contains statements which constitute “forward-looking information” within the meaning of Canadian and U.S. securities laws, including statements regarding the plans, intentions, beliefs and current expectations of Harvest with respect to future business activities. Forward-looking information is often identified by the words “may,” “would,” “could,” “should,” “will,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “expect” or similar expressions and include information regarding: (i) expectations regarding the size of the U.S. cannabis market, (ii) the ability of Harvest to successfully achieve its business objectives, (iii) plans for expansion of Harvest, and (iv) expectations for other economic, business, and/or competitive factors.
Investors are cautioned that forward-looking information is not based on historical facts but instead reflects Harvest management’s expectations, estimates or projections concerning future results or events based on the opinions, assumptions and estimates of management considered reasonable at the date the statements are made. Although Harvest believes that the expectations reflected in such forward-looking information are reasonable, such information involves risks and uncertainties, and undue reliance should not be placed on such information, as unknown or unpredictable factors could have material adverse effects on future results, performance or achievements of the combined Company. Among the key factors that could cause actual results to differ materially from those projected in the forward-looking information are the following: the effects of the weather, natural disasters, and health pandemics, including the novel coronavirus (COVID-19), on customer demand, Harvest’s supply chain as well as its consolidated results of operation, financial position and cash flows, the ability of Harvest to develop Harvest’s brand and meet its revenue, growth and profitability objectives, the ability of Harvest to locate and execute acquisitions of companies, properties or assets that are accretive to its revenue and business objectives, the ability of Harvest to obtain and/or maintain licenses or other contractual rights to operate in the jurisdictions in which it operates or in which it expects or plans to operate; changes in general economic, business and political conditions, including changes in the financial markets; and in particular in the ability of Harvest to raise debt and equity capital in the amounts needed and at the costs that it expects; adverse changes in the public perception of cannabis; decreases in the prevailing prices for cannabis and cannabis products in the markets that Harvest operates in; adverse changes in applicable laws; or adverse changes in the application or enforcement of current laws, including those related to taxation; and increasing costs of compliance with extensive government regulation.
 These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. In addition, even if the outcome and financial effects of the plans and events described herein are consistent with the forward-looking statements contained in this press release, those results or developments may not be indicative of results or developments in subsequent periods. Although Harvest has attempted to identify important risks and factors that could cause actual actions, events or results to differ materially from those described in forward-looking information, there may be other factors and risks that cause actions, events or results not to be as anticipated, estimated or intended. Forward-looking information contained in this press release is based on Harvest’s current estimates, expectations and projections, which Harvest believes are reasonable as of the current date. Harvest can give no assurance that these estimates, expectations and projections will prove to have been correct. You should not place undue reliance on forward-looking statements, which are based on the information available as of the date of this press release. Forward-looking statements contained in this press release are made of the date of this press release and, except as required by applicable law, Harvest assumes no obligation to update or revise them to reflect new events or circumstances. Historical statements contained in this press release regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. In this regard, certain financial information contained herein has been extracted from, or based upon, information available in the public domain and/or provided by Harvest. In particular historical results should not be taken as a representation that such trends will be replicated in the future. No statement in this press release is intended to be a profit forecast. While the information contained herein is believed to be accurate, Harvest, its affiliates, and their respective stockholders, members, partners, directors, managers, officers, employees, agents, advisors, and other representatives each expressly disclaims any and all liability for representations, expressed or implied, contained in or omitted from this press release or any other written or oral communications transmitted to any interested party in the course of its evaluation of Harvest. Nothing contained herein is or shall be relied upon as a promise or representation by Harvest or their affiliates or any of their respective stockholders, members, partners, directors, managers, officers, employees, agents, advisors, or other representatives as to the past or future performance of Harvest. Only those particular representations and warranties made by Harvest in a written definitive agreement, when and if one is executed, and subject to such limitations and restrictions as may be specified in such agreement, shall have any legal effect
.

This forward-looking information may be affected by risks and uncertainties in the business of Harvest and market conditions.
Please see the heading “Risk Factors” in our Canadian filings, and the heading “Item 1A. Risk Factors” in our Form 10, filed with the U.S. Securities and Exchange Commission on November 5, 2020, as well as our subsequent filings in the United States and Canada, for a discussion of material risk factors that could cause actual results to differ materially from the forward-looking information.
Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking information prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated or expected. Although Harvest has attempted to identify important risks, uncertainties and factors which could cause actual results to differ materially, there may be others that cause results not to be as anticipated, estimated or intended. Harvest does not intend, and does not assume any obligation, to update this forward-looking information except as otherwise required by applicable law.

View original content to download multimedia:http://www.prnewswire.com/news-releases/harvest-health–recreation-inc-announces-settlement-with-minority-owners-of-interurban-capital-group-301177803.html

SOURCE Harvest Health & Recreation Inc.

ELKHART, Ind., Nov. 20, 2020 /PRNewswire/ — Patrick Industries, Inc. (NASDAQ: PATK) (the “Company”), a major manufacturer and distributor of component and building products for the recreational vehicle, marine, manufactured housing and industrial markets, today announced that on November 19, 2020, its Board of Directors (the “Board”) approved an increase in the amount of its quarterly cash dividend on its common stock to $0.28 per share from $0.25 per share. The dividend is payable on December 14, 2020, to shareholders of record at the close of business on November 30, 2020.

“In alignment with our capital allocation strategy, the decision to increase the dividend reflects the continued confidence of both management and the Board in the Company’s strategic and financial position and the strength of our cash flows, and represents our ongoing commitment to increasing long-term shareholder value,” said Andy Nemeth, President and Chief Executive Officer of Patrick.

About Patrick Industries, Inc.
Patrick Industries, Inc. is a major manufacturer and distributor of component products and building products serving the recreational vehicle, marine, manufactured housing, residential housing, high-rise, hospitality, kitchen cabinet, office and household furniture, fixtures and commercial furnishings, and other industrial markets and operates coast-to-coast in various locations throughout the United States and in Canada, China and the Netherlands. Patrick’s major manufactured products include decorative vinyl and paper laminated panels, countertops, fabricated aluminum products, wrapped profile mouldings, slide-out trim and fascia, cabinet doors and components, hardwood furniture, fiberglass bath fixtures and tile systems, thermoformed shower surrounds, specialty bath and closet building products, fiberglass and plastic helm systems and component products, wiring and wire harnesses, boat covers, towers, tops and frames, electrical systems components including instrument and dash panels, softwoods lumber, interior passage doors, air handling products, RV painting, slotwall panels and components, aluminum fuel tanks, and CNC molds and composite parts and other products. The Company also distributes drywall and drywall finishing products, electronics and audio systems components, wiring, electrical and plumbing products, appliances, cement siding, raw and processed lumber, FRP products, interior passage doors, roofing products, tile, laminate and ceramic flooring, shower doors, furniture, fireplaces and surrounds, interior and exterior lighting products, and other miscellaneous products, in addition to providing transportation and logistics services.

Cautionary Statement Regarding Forward-Looking Statements
This press release contains certain statements related to future results, our intentions, beliefs and expectations or predictions for the future, which are forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any projections of financial performance or statements concerning expectations as to future developments should not be construed in any manner as a guarantee that such results or developments will, in fact, occur. There can be no assurance that any forward-looking statement will be realized or that actual results will not be significantly different from that set forth in such forward-looking statement. Information about certain risks that could affect our business and cause actual results to differ from those expressed or implied in the forward-looking statements are contained in the section entitled “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019, and in the Company’s Forms 10-Q for subsequent quarterly periods, which are filed with the Securities and Exchange Commission (“SEC”) and are available on the SEC’s website at www.sec.gov. In addition, future dividends are subject to Board approval. Each forward-looking statement speaks only as of the date of this press release, and we undertake no obligation to update any forward-looking statement to reflect events or circumstances occurring after the date on which it is made.

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/patrick-industries-inc-announces-increase-to-regular-quarterly-cash-dividend-301177994.html

SOURCE Patrick Industries, Inc.

SEATTLE, Nov. 20, 2020 /PRNewswire/ — Starting this spring, Alaska Airlines and American Airlines will make it a more hassle-free, rewarding experience for elite guests from one airline to travel on the other, with new benefits that will roll out during 2021.

As part of the enhancements, Alaska’s MVP Gold 75K, MVP Gold and MVP Mileage Plan members will be able to access premium seating, and MVP Gold 75Ks will be eligible for upgrades, when they book flights on American’s domestic and international routes. Travelers can take advantage of these benefits on itineraries that are solely on American or when connecting to an American flight. 

Here’s some of what’s to come:

• In the spring, all Alaska elite members will receive complimentary access to preferred seats when traveling on American Airlines, including Main Cabin Extra.
• Alaska MVP Gold 75K members will be eligible to earn global upgrade certificates that can be used to move from the main cabin to Business Class on American. For example, one of those certificates can be redeemed to upgrade from the main cabin to Business Class on American’s new nonstop international service from Seattle to London or Seattle to Shanghai in spring 2021, based on availability.
• Later in 2021, Alaska MVP Gold 75K members will be eligible for unlimited complimentary, space available upgrades to Business or First Class when traveling on American’s domestic flights.

These benefits will be in addition to the elite perks offered as part of Alaska’s membership in the oneworld global alliance, which takes effect on March 31, 2021. As a oneworld member, Alaska’s elite travelers will be able to take advantage of priority services, international lounge access and baggage benefits.

“Our upcoming membership in oneworld makes these added benefits with American even more rewarding for our guests,” said Andrew Harrison, executive vice president and chief commercial officer. “On any American flight, our elites will have access to premium seating or a possible upgrade for a more comfortable journey, in addition to other perks.” 

American’s AAdvantage program elite members will receive reciprocal benefits on Alaska. 

“Alaska and American are improving our service on the West Coast so that customers can enjoy their loyalty benefits on either carrier,” said Vasu Raja, American’s chief revenue officer. “Next year will bring significant enhancements that will make the experience more seamless and rewarding for our customers traveling to, through or from the West Coast.”

The expanded relationship between Alaska and American was first announced in February 2020. In fall 2021, American will begin its inaugural service from Seattle to Bangalore, India – connecting two global technology hubs. 

Alaska Airlines and its regional partners serve more than 115 destinations across the United States and North America. The airline provides essential air service for our guests along with moving crucial cargo shipments, while emphasizing Next-Level Care. Alaska is known for low fares, award-winning customer service and sustainability efforts. Guests can earn and redeem miles on flights to more than 800 destinations worldwide with Alaska and its Global Partners. On March 31, 2021, Alaska will officially become a member of the oneworld global alliance. Learn more about Alaska at newsroom.alaskaair.com and blog.alaskaair.com. Alaska Airlines and Horizon Air are subsidiaries of Alaska Air Group (NYSE: ALK).

 

View original content:http://www.prnewswire.com/news-releases/alaska-airlines-elite-flyers-will-earn-added-benefits-on-american-airlines-in-2021-301177906.html

SOURCE Alaska Airlines

PLYMOUTH MEETING, Pa., Nov. 20, 2020 /PRNewswire/ — INOVIO (NASDAQ: INO), a biotechnology company focused on rapidly bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases and cancer, announced today that data from the company’s novel combination trial of DNA medicines INO-5401 and INO-9012 in combination with PD-1 inhibitor Libtayo^® (cemiplimab) in the treatment of newly diagnosed glioblastoma (GBM), will be presented by Dr. David Reardon in the plenary session at the Society for Neuro-Oncology (SNO) 2020 Annual Meeting. The study demonstrated that INO-5401 + INO-9012 with Libtayo, radiation (RT) and temozolomide (TMZ) are tolerable, immunogenic, and may improve median survival for patients with newly diagnosed GBM. Survival data at 18 months showed that 70% (14/20) of MGMT promoter methylated GBM patients were alive, and 50% (16/32) of MGMT promoter unmethylated patients, which are the more difficult to treat group, were alive after 18 months. Median overall survival in the unmethylated GBM patients was 17.9 months, which compares favorably to historical controls; Median OS for methylated patients has not yet been reached and the study is ongoing.

Dr. David Reardon, Clinical Director of the Center for Neuro-Oncology at the Dana-Farber Cancer Institute and coordinating principal investigator of GBM-001 said, “This is a landmark combination trial in which a novel DNA vaccine is combined with a checkpoint inhibitor and radiation and chemotherapy. We look forward to continuing to review these data, with an eye towards those patients who are most likely to benefit from this innovative approach and to see whether, over time, there is an extension of survival in these very hard-to-treat patients. Coupling immune response with clinical outcome may prove insightful.”

Interim data demonstrated that in the MGMT promoter unmethylated cohort, 19/22 (86%) subjects to date had an IFN-gamma T cell response that increased over baseline to one or more of the antigens encoded by INO-5401. In the MGMT promoter methylated cohort, 16/17 (94%) subjects to date had an IFN-gamma response that increased over baseline to one or more of the antigens encoded by INO-5401. The novel combination of INO-5401 + INO-9012 continues to demonstrate a well-tolerated safety profile when given not only with radiation and TMZ, but also with PD-1 blockade by Libtayo, which is being jointly developed by Regeneron and Sanofi.

Dr. Jeffrey Skolnik, INOVIO’s senior vice president, clinical development, said, “INO-5401 + INO-9012, with Libtayo and RT/TMZ, generates cancer antigen-specific T cells that may be able to attack GBM and provide a survival advantage. We are using our knowledge of immunology to define a patient population for which this novel DNA medicine plus checkpoint inhibitor combination may offer a survival advantage, by continuing to assess all of our data: efficacy, safety and most important, immunogenicity and tissue expression data.”

Additional data will be provided in the coming months, including correlative immunology and tissue data, as well as total study drug exposure and concomitant medication use.

INO-5401, INO-9012 and Libtayo, and the combination of these products have not been approved or evaluated by any Regulatory Authority worldwide for the treatment of newly diagnosed GBM.

Presentation Details

Abstract: LTBK-01

Title: “INO-5401 and INO-9012 delivered intramuscularly (IM) with electroporation (EP) in combination with cemiplimab (REGN2810) in newly diagnosed glioblastoma”

Presenting Author: Dr. David Reardon
Plenary Session Date and Time: 2020 SNO Annual Meeting, Plenary 1A, Friday, November 20, 2020 beginning at 11 a.m. EST

Study Design

The trial was designed to evaluate safety, immunogenicity and efficacy of INO-5401 and INO-9012 in combination with Libtayo, with radiation and chemotherapy, in subjects with newly diagnosed glioblastoma (GBM). This is a Phase 1/2, open-label, multi-center trial conducted in 52 evaluable patients with GBM. There are two cohorts in this trial. Cohort A includes 32 participants with a tumor with an unmethylated O6-methylguanine-deoxyribonucleic acid (DNA) methyltransferase (MGMT) promoter. Cohort B includes 20 participants with a tumor with a MGMT methylated promoter. Both cohorts received INO-5401 and INO-9012 and Libtayo at the same doses and on the same dosing schedule, and both cohorts received radiation and TMZ. For more information of the clinical study, see www.clinicaltrials.gov, identifier NCT03491683.

About Glioblastoma Multiforme (GBM)

GBM is the most common and aggressive type of brain cancer and remains a devastating disease for both patients and caregivers. Its prognosis is extremely poor, despite a limited number of new therapies approved over the last 10 years. The median overall survival for patients receiving standard of care therapy is approximately 15 to 22 months and the median progression-free survival is approximately 7 months. In the U.S., the estimated annual incidence of GBM is 11,362 cases or 3.21 cases per 100,000 persons and the median age at diagnosis is 65 years.

About INO-5401 and INO-9012

INO-5401 encodes for INOVIO’s SynCon^® antigens for hTERT, WT1, and PSMA, and has the potential to be a powerful cancer immunotherapy in combination with checkpoint inhibitors. The National Cancer Institute previously highlighted hTERT, WT1, and PSMA among a list of important cancer antigens, designating them as high priorities for cancer immunotherapy development. These three antigens were reported to be over-expressed, and often mutated, in a variety of human cancers, and targeting these antigens may prove efficacious in the treatment of patients with cancer. INO-9012 encodes for IL-12, which is a T cell immune activator.

About INOVIO’s DNA Medicines Platform

INOVIO has 15 DNA medicine clinical programs currently in development focused on HPV-associated diseases, cancer, and infectious diseases, including coronaviruses associated with MERS and COVID-19 diseases being developed under grants from the Coalition for Epidemic Preparedness Innovations (CEPI) and the U.S. Department of Defense. DNA medicines are composed of optimized DNA plasmids, which are small circles of double-stranded DNA that are synthesized or reorganized by a computer sequencing technology and designed to produce a specific immune response in the body.

INOVIO’s DNA medicines deliver optimized plasmids directly into cells intramuscularly or intradermally using INOVIO’s proprietary hand-held smart device called CELLECTRA®. The CELLECTRA device uses a brief electrical pulse to reversibly open small pores in the cell to allow the plasmids to enter, overcoming a key limitation of other DNA and other nucleic acid approaches, such as mRNA. Once inside the cell, the DNA plasmids enable the cell to produce the targeted antigen. The antigen is processed naturally in the cell and triggers the desired T cell and antibody-mediated immune responses. Administration with the CELLECTRA device ensures that the DNA medicine is efficiently delivered directly into the body’s cells, where it can go to work to drive an immune response. INOVIO’s DNA medicines do not interfere with or change in any way an individual’s own DNA. The advantages of INOVIO’s DNA medicine platform are how fast DNA medicines can be designed and manufactured; the stability of the products, which do not require freezing in storage and transport; and the robust immune response, safety profile, and tolerability that have been observed in clinical trials.

With more than 2,000 patients receiving INOVIO investigational DNA medicines in more than 7,000 applications across a range of clinical trials, INOVIO has a strong track record of rapidly generating DNA medicine candidates with potential to meet urgent global health needs.

About INOVIO

INOVIO is a biotechnology company focused on rapidly bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, cancer, and diseases associated with HPV. INOVIO is the first and only company to have clinically demonstrated that a DNA medicine can be delivered directly into cells in the body via a proprietary smart device to produce a robust and tolerable immune response. Specifically, INOVIO’s lead candidate VGX-3100, currently in Phase 3 trials for precancerous cervical dysplasia, destroyed and cleared high-risk HPV 16 and 18 in a Phase 2b clinical trial. High-risk HPV is responsible for 70% of cervical cancer, 91% of anal cancer, and 69% of vulvar cancer. Also in development are programs targeting HPV-related cancers and a rare HPV-related disease, recurrent respiratory papillomatosis (RRP); non-HPV-related cancers glioblastoma multiforme (GBM) and prostate cancer; as well as externally funded infectious disease DNA vaccine development programs in Zika, Lassa fever, Ebola, HIV, and coronaviruses associated with MERS and COVID-19 diseases. Partners and collaborators include Advaccine, ApolloBio Corporation, AstraZeneca, The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations (CEPI), Defense Advanced Research Projects Agency (DARPA)/Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND)/Department of Defense (DOD), HIV Vaccines Trial Network, International Vaccine Institute (IVI), Medical CBRN Defense Consortium (MCDC), National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Ology Bioservices, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron, Richter-Helm BioLogics, Thermo Fisher Scientific, University of Pennsylvania, Walter Reed Army Institute of Research, and The Wistar Institute. INOVIO also is a proud recipient of 2020 Women on Boards “W” designation recognizing companies with more than 20% women on their board of directors. For more information, visit www.inovio.com.

CONTACTS: 
Investors: Ben Matone, 484-362-0076, [email protected] 
Media: Jeff Richardson, 267-440-4211, [email protected]

This press release contains certain forward-looking statements relating to our business, including our plans to develop DNA medicines, our expectations regarding our research and development programs, including the planned initiation and conduct of preclinical studies and clinical trials and the availability and timing of data from those studies and trials, and our ability to successfully manufacture and produce large quantities of our product candidates if they receive regulatory approval. Actual events or results may differ from the expectations set forth herein as a result of a number of factors, including uncertainties inherent in pre-clinical studies, clinical trials, product development programs and commercialization activities and outcomes, our ability to secure sufficient manufacturing capacity to mass produce our product candidates, the availability of funding to support continuing research and studies in an effort to prove safety and efficacy of electroporation technology as a delivery mechanism or develop viable DNA medicines, our ability to support our pipeline of DNA medicine products, the ability of our collaborators to attain development and commercial milestones for products we license and product sales that will enable us to receive future payments and royalties, the adequacy of our capital resources, the availability or potential availability of alternative therapies or treatments for the conditions targeted by us or our collaborators, including alternatives that may be more efficacious or cost effective than any therapy or treatment that we and our collaborators hope to develop, issues involving product liability, issues involving patents and whether they or licenses to them will provide us with meaningful protection from others using the covered technologies, whether such proprietary rights are enforceable or defensible or infringe or allegedly infringe on rights of others or can withstand claims of invalidity and whether we can finance or devote other significant resources that may be necessary to prosecute, protect or defend them, the level of corporate expenditures, assessments of our technology by potential corporate or other partners or collaborators, capital market conditions, the impact of government healthcare proposals and other factors set forth in our Annual Report on Form 10-K for the year ended December 31, 2019, our Quarterly Report on Form 10-Q for the quarter ended September 30, 2020 and other filings we make from time to time with the Securities and Exchange Commission. There can be no assurance that any product candidate in our pipeline will be successfully developed, manufactured or commercialized, that final results of clinical trials will be supportive of regulatory approvals required to market products, or that any of the forward-looking information provided herein will be proven accurate. Forward-looking statements speak only as of the date of this release, and we undertake no obligation to update or revise these statements, except as may be required by law.

 

View original content:http://www.prnewswire.com/news-releases/inovio-presents-clinical-results-of-its-dna-medicines-ino-5401–ino-9012-in-novel-combination-with-pd-1-inhibitor-libtayo-cemiplimab-in-the-treatment-of-newly-diagnosed-glioblastoma-multiforme-at-society-for-neuro-oncology-202-301177899.html

SOURCE INOVIO Pharmaceuticals, Inc.

ATLANTIC CITY, N.J., Nov. 20, 2020 /PRNewswire/ — Harrah’s Resort Atlantic City celebrates its 40th anniversary this weekend, commemorating four decades of achievements and milestones. Beloved by generations across the tri-state area, the premier bayside resort destination has evolved to meet the ever-changing demand for new experiences and to reach new audiences. Over the years, Harrah’s Resort has hosted hundreds of signature events, welcoming guests, countless celebrities, and many notable guests through the years, making it a must-see hotel and casino in Atlantic City. What’s more, the popular destination offers award-winning restaurants with an array of accommodation options, including the newly renovated Laguna and Coastal towers, showcasing stunning Bay views.

**For high-res photos, click



here



**

On the heels of the resort’s latest hotel renovation, the newly-formed Caesars Entertainment (NASDAQ: CZR) recently announced its commitment to $400 million in total capital investments and improvements into its Atlantic City resorts – Caesars, Tropicana, and Harrah’s Resort – over the next three years.

Last month, Harrah’s Resort received notable recognition by being voted one of the country’s Top 10 Casinos Outside Las Vegas by USA Today’s 10 Best Readers Poll. Additionally, Caesars Rewards received top accolades as the #1 Best Players Club in the nation for the third consecutive year, strengthened by the property having the loosest slots in Atlantic City*, offering the highest total slot payback percentage in the seaside gaming town for the seventh year straight.  (*Based on NJ DGE monthly revenue statistics & Strictly Slots magazine).

“With three premier resorts in the market, and as the largest employer in Atlantic County, Atlantic City is critical to the success of Caesars Entertainment,” said Steve Callender, Regional President for Caesars Entertainment.  “Under the newly-formed Caesars Entertainment, we have over 60 million Caesars Rewards customers, many of whom live within driving distance of our properties.  Having spent my entire career in the City, I have a special appreciation of this landmark 40th anniversary for Harrah’s Resort, the gaming industry and Atlantic City. 2020 has presented us with challenges unlike anything we have endured before over the past four decades.  I am extremely grateful and proud of the teams at Harrah’s, Tropicana and Caesars, who continue to deliver first-class service to our guests, while putting health and safety at the forefront of the experience,” he added.

“For almost half a century now, Harrah’s Resort has been committed to Atlantic City and has helped lead the way in positioning the city as a leading gaming & entertainment destination on the East Coast,” explained Ron Baumann, Senior Vice President & General Manager for Caesars & Harrah’s Resort.  “But most importantly, however, is our dedication to helping make the community we serve a great place to both work and play.  Through all the ebbs and flows this market has seen, including the unprecedented times we are living through right now, Harrah’s has continued to thrive over the last 40 years, and we attribute much of our success to our day-one employees who deliver top-notch service to our guests each day, and our loyal customers. While the celebration may look a bit different this year, we are unbelievably proud of our team members and thank our customers for their loyalty.”

A 40-Year Legacy

For the past 40 years, Harrah’s has hit many notable milestones; however, the destination is most proud to be home to 40 day one team members who have been with the company from the first day the resort opened its doors and are actively working right now. For more than four decades, these legacy team members have delivered superior customer service and a welcoming smile that Harrah’s loyal customers have come to know and love. 

Known for delivering exceptional entertainment and dining, Harrah’s Resort Atlantic City continues to offer guests curated experiences through an impressive roster of fine dining establishments. A notable restaurant is Gordon Ramsay Steak, celebrating two years as one of Atlantic City’s only two restaurants by a Michelin Star chef, and his only restaurants in the tri-state region. The celebrated television personality and 7-Michelin star chef opened his first steakhouse concept at Harrah’s in 2018.

“For me, Gordon Ramsay Steak at Harrah’s Resort has been one of the most exciting steak houses I’ve ever opened. Thank you to Caesars Entertainment for being a great partner, the team at Harrah’s helping bring this vision to life, and to our customers for their loyalty. I know this year has been difficult, but I can’t wait to get back to Harrah’s to help celebrate their 40th birthday.”- Gordon Ramsay

When Harrah’s doors reopened in July and outside dining was a premier amenity, the team found a creative way to give Gordon Ramsay Steak a “breath of fresh air” with a pop-up experience on the rooftop of the resort’s famed Pool, offering al fresco dining “Under The Stars.”

As of November 2020, Gordon Ramsay Steak has crossed off some exceptional milestones, including:

• Served 126,234 ounces of Wagyu Beef (equal to 7,889 pounds)
• Sold 87,000 steaks and are approaching 90,000 this month.
• Served 12,810 Sticky Toffee Puddings signature desserts
• Served 12,030 Beef Wellingtons
• Will serve its 150,000 dining cover this month

In addition to Gordon Ramsay Steak, Harrah’s Resort offers an array of dining options ranging from fine dining to quick-service, including Martorano’s, Guy’s Sammich Joint by Guy Fieri, A.C. Burger Co., Coastal Craft Kitchen & Bar, and more.

A 40-Year Commitment To The Community

Since opening its doors on November 22, 1980, Harrah’s Resort Atlantic City has been committed to building a strong South Jersey community. In 2019, the resort supported hundreds of community organizations while empowering team members to do the same. Additionally, Harrah’s strives to do their part to protect the environment through its industry-leading Code Green initiative – part of the company’s People, Planet, Play platform – that translates to an eco-friendly guestroom experience and LEED-certified $125 million Waterfront Conference Center.

When Atlantic City casinos closed their doors in April, Caesars Entertainment Atlantic City Resorts launched a large-scale relief effort to support the community and donated over 95% of its perishable food to local organizations. Caesars Entertainment and its employee volunteers delivered over 40,000 pounds of food, including fresh dairy, produce, canned goods, and lunch meat to those in need at The Community Food Bank of Southern NJ, The Salvation Army, and The Atlantic City Rescue Mission Food.  To ensure nothing was wasted, recently perished items were donated to The Funny Farm Animal Rescue in Mays Landing, NJ. 

Recently, the company has focused on helping to fight food insecurity in the area, where the pandemic has impacted many residents throughout Atlantic County, starting with its recent $5,527 donation to The Community Food Bank of N.J. (Egg Harbor Township), where a portion of ticket sales from Harrah’s Bayside Rock Live outdoor concert series were donated.

Further extending their commitment to the community, Harrah’s Resort has delivered premade sandwiches to over 12 organizations in the area each week, led by the culinary team at Harrah’s. The sandwiches will be used for lunches to support the new after school program and teen center at the Boys & Girls Club and assist non-profits in area fighting food insecurity and homelessness in Atlantic City. Recently, more than 180 sandwiches were donated to Covenant House, a place that provides youth homeless shelters in the city, and 150 sandwiches were recently delivered to Turning Point, an organization dedicated to combating homelessness in the city, and will continue on a weekly basis as needed. By the end of the year, nearly 20,000 items will be distributed to organizations in Atlantic City.

Rewards and Celebrations – 40-year accomplishments

Harrah’s Resort in Atlantic City is known for attracting A-list celebrity hosts, D.J.s, and performers straight off the Billboard Hot 100. Celebrities known to frequent the Harrah’s Resort grounds include Paris Hilton, DJ Pauly D, Brody Jenner, stars of Vanderpump Rules James Kennedy, Tom Sandoval, Tom Schwartz, and more.

Caesars Entertainment Atlantic City destinations, including Harrah’s Resort, are pacing to commemorate the distribution of its one millionth mask this weekend – having collectively distributed a million masks to team members and customers since reopening at Harrah’s, Caesars, and Tropicana. This milestone illustrates the company’s commitment to keeping their employees and guests safe.

As a thank you to their guests who have made Harrah’s Resort Atlantic City an iconic destination, the resort is holding a promotion every Saturday this month where the property will give away 40,000 rewards credits every 40 minutes from 12 p.m. – 8 p.m.

Additionally, Harrah’s Resort Atlantic City is offering several other promotions including up to 40% off for stays 30+ days in advance, a 2-night stay for $99, and more. For all deals, visit www.caesars.com/harrahs-ac

For additional information on what’s open in Atlantic City, visit www.caesars.com/atlantic-city/open

About Caesars Entertainment

Caesars Entertainment is one of the world’s most diversified casino-entertainment providers and the most geographically diverse U.S. casino-entertainment company. Since its beginning in Reno, Nevada, in 1937, Caesars Entertainment has grown through development of new resorts, expansions and acquisitions. Caesars Entertainment’s resorts operate primarily under the Caesars®, Harrah’s® and Horseshoe® brand names. Caesars Entertainment’s portfolio also includes the Caesars Entertainment U.K. family of casinos. Caesars Entertainment is focused on building loyalty and value with its guests through a unique combination of great service, excellent products, unsurpassed distribution, operational excellence and technology leadership. Caesars Entertainment is committed to its employees, suppliers, communities and the environment through its PEOPLE PLANET PLAY framework. For more information, please visit www.caesars.com/corporate.

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/harrahs-resort-atlantic-city-celebrates-40th-anniversary-301177791.html

SOURCE Caesars Entertainment, Inc.

LOS ANGELES, Nov. 20, 2020 /PRNewswire/ — Canoo Holdings Ltd. (“Canoo”), a company developing breakthrough electric vehicles (EV) with a proprietary and highly versatile skateboard platform for personal and business use, announced today it will present at the Jefferies Virtual Truck Summit. Members of management will present Monday, November 23, at 10:00 a.m. ET. To access the event please contact your Jefferies sales representative.

Canoo has previously announced a merger agreement with Hennessy Capital Acquisition Corp. IV (“HCAC”) (Nasdaq: HCAC), a special purpose acquisition company (SPAC), that would result in Canoo becoming a publicly listed company.

About Canoo

Canoo is a Los Angeles-based company that has developed breakthrough electric vehicles, reinventing the automotive landscape with bold innovations in design, pioneering technologies, and a unique business model that defies traditional ownership to put customers first. Distinguished by its experienced team – numbering  over 300 employees from leading technology and automotive companies – Canoo has designed a modular skateboard platform purpose-built to deliver maximum vehicle interior space and adaptable to support a wide range of vehicle applications for consumers and businesses. Canoo expects to launch its first consumer model in 2022, followed shortly after by a last-mile delivery vehicle and a sport vehicle, each built off of the same underlying skateboard platform.

For more information, please visit www.canoo.com.

For Canoo press materials, including photos, please visit press.canoo.com.

For investors, please visit investors.canoo.com.

Forward Looking Statements
The information in this press release includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as “estimate,” “plan,” “project,” “forecast,” “intend,” “will,” “expect,” “anticipate,” “believe,” “seek,” “target” or other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding estimates and forecasts of financial and performance metrics, projections of market opportunity and market share, expectations and timing related to commercial product launches, ability to accelerate Canoo’s go-to-market strategy and capitalize on commercial opportunities, potential benefits of the transaction and the potential success of Canoo’s go-to-market strategy, and expectations related to the terms and timing of completing the transaction. These statements are based on various assumptions, whether or not identified in this press release, and on the current expectations of Canoo’s and HCAC’s management and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by any investor as, a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. Many actual events and circumstances are beyond the control of Canoo and HCAC. These forward-looking statements are subject to a number of risks and uncertainties, including changes in domestic and foreign business, market, financial, political and legal conditions; the inability of the parties to successfully or timely consummate the proposed business combination, including the risk that any required regulatory approvals are not obtained, are delayed or are subject to unanticipated conditions that could adversely affect the combined company or the expected benefits of the proposed business combination or that the approval of the stockholders of HCAC or Canoo is not obtained; failure to realize the anticipated benefits of the proposed business combination; risks relating to the uncertainty of the projected financial information with respect to Canoo; risks related to the rollout of Canoo’s business and the timing of expected business milestones and commercial launch; risks related to future market adoption of Canoo’s offerings; risks related to Canoo’s go-to-market strategy and subscription business model; the effects of competition on Canoo’s future business; the amount of redemption requests made by HCAC’s public stockholders; the ability of HCAC or the combined company to issue equity or equity-linked securities in connection with the proposed business combination or in the future, and those factors discussed in HCAC’s final prospectus filed on March 4, 2019, Annual Report on Form 10-K for the fiscal year ended December 31, 2019 and Quarterly Reports on Form 10-Q for the quarters ended March 31, 2020 and June 30, 2020, the registration statement on Form S-4 (together with all amendments thereto, the “Registration Statement”) initially filed on September 18, 2020, and the preliminary proxy statement / prospectus contained therein, in each case, under the heading “Risk Factors,” and other documents of HCAC filed, or to be filed, with the Securities and Exchange Commission (“SEC”). If any of these risks materialize or our assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. There may be additional risks that neither HCAC nor Canoo presently know or that HCAC and Canoo currently believe are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. In addition, forward-looking statements reflect HCAC’s and Canoo’s expectations, plans or forecasts of future events and views as of the date of this press release. HCAC and Canoo anticipate that subsequent events and developments will cause HCAC’s and Canoo’s assessments to change. However, while HCAC and Canoo may elect to update these forward-looking statements at some point in the future, HCAC and Canoo specifically disclaim any obligation to do so. These forward-looking statements should not be relied upon as representing HCAC’s and Canoo’s assessments as of any date subsequent to the date of this press release. Accordingly, undue reliance should not be placed upon the forward-looking statements.

Important Information for Investors and Shareholders
In connection with the proposed business combination, HCAC has filed the Registration Statement with the SEC. Additionally, HCAC will file other relevant materials with the SEC in connection with the business combination. Copies may be obtained free of charge at the SEC’s web site at www.sec.gov. Security holders of HCAC are urged to read the Registration Statement and the other relevant materials when they become available before making any voting decision with respect to the proposed business combination because they will contain important information about the business combination and the parties to the business combination. The information contained on, or that may be accessed through, the websites referenced in this press release is not incorporated by reference into, and is not a part of, this press release.

Participants in the Solicitation
HCAC and its directors and officers may be deemed participants in the solicitation of proxies of HCAC’s stockholders in connection with the proposed business combination. Security holders may obtain more detailed information regarding the names, affiliations and interests of certain of HCAC’s executive officers and directors in the solicitation by reading HCAC’s Annual Report on Form 10-K for the fiscal year ended December 31, 2019, and the Registration Statement and other relevant materials filed with the SEC in connection with the business combination when they become available. Information concerning the interests of HCAC’s participants in the solicitation, which may, in some cases, be different than those of their stockholders generally, are set forth in the Registration Statement.

View original content to download multimedia:http://www.prnewswire.com/news-releases/electric-vehicle-company-canoo-to-present-at-the-jefferies-virtual-truck-summit-301177778.html

SOURCE Canoo

DALLAS, Nov. 20, 2020 /PRNewswire/ — Ashford Hospitality Trust, Inc. (NYSE: AHT) (“Ashford Trust” or the “Company”) announced today that it was notified by the New York Stock Exchange (the “NYSE”) that the Company has been in full compliance with all of the NYSE’s continued listing standards, as indicated in a letter delivered to the Company on November 19, 2020.    

As previously disclosed, on October 1, 2020, the Company received notification (the “Initial Letter”) from the NYSE that it was not in compliance with the continued listing standards set forth in the NYSE Listed Company Manual (the “Company Manual”). Specifically, the Initial Letter stated that the Company was not in compliance with Section 802.01B of the Company Manual, which requires a listed company to have an average market capitalization of not less than $50 million over a 30 trading-day period and, at the same time, stockholders’ equity of not less than $50 million.

On November 19, 2020, the NYSE sent a letter to the Company (the “Correction Letter”) stating that the NYSE had incorrectly stated in the Initial Letter that the Company was below compliance with the quantitative continued listing criteria for operating companies as set forth in Section 802.01B of the Company Manual. In the Correction Letter, the NYSE noted that in making its determination provided in the Initial Letter, the NYSE did not consider that the Company is a Real Estate Investment Trust (“REIT”) and that, given the Company’s REIT status, the quantitative continued listing standards for operating companies do not apply.

Additionally, the NYSE stated in the Correction Letter that it intends to promptly remove the “.BC” indicator that has been appended to the Company’s symbol on the consolidated tape and on the NYSE website as a result of the Initial Letter.

Ashford Hospitality Trust is a real estate investment trust (REIT) focused on investing predominantly in upper upscale, full-service hotels.

Ashford has created an Ashford App for the hospitality REIT investor community. The Ashford App is available for free download at Apple’s App Store and the Google Play Store by searching “Ashford.”

Certain statements and assumptions in this press release contain or are based upon “forward-looking” information and are being made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release include, among others, statements about the Company’s strategy and future plans. These forward-looking statements are subject to risks and uncertainties. When we use the words “will likely result,” “may,” “anticipate,” “estimate,” “should,” “expect,” “believe,” “intend,” or similar expressions, we intend to identify forward-looking statements. Such statements are subject to numerous assumptions and uncertainties, many of which are outside Ashford Trust’s control.

These forward-looking statements are subject to known and unknown risks and uncertainties, which could cause actual results to differ materially from those anticipated, including, without limitation: the impact of the novel strain of coronavirus (COVID-19) on our business; the ability of the Company and the Company’s advisor, Ashford Inc., to continue as a going concern; the timing and outcome of the Securities and Exchange Commission’s investigation; our ability to meet the NYSE continued listing standards; our ability to repay, refinance or restructure our debt and the debt of certain of our subsidiaries; general volatility of the capital markets and the market price of our common stock and preferred stock; changes in our business or investment strategy; availability, terms and deployment of capital; availability of qualified personnel; changes in our industry and the market in which we operate, interest rates or the general economy; and the degree and nature of our competition. These and other risk factors are more fully discussed in Ashford Trust’s filings with the Securities and Exchange Commission.

The forward-looking statements included in this press release are only made as of the date of this press release. Investors should not place undue reliance on these forward-looking statements. We will not publicly update or revise any forward-looking statements, whether as a result of new information, future events or circumstances, changes in expectations or otherwise except to the extent required by law.

View original content:http://www.prnewswire.com/news-releases/ashford-hospitality-trust-inc-receives-notice-that-company-has-been-in-full-compliance-with-nyse-continued-listing-standards-301177999.html

SOURCE Ashford Hospitality Trust, Inc.

ATLANTA, Nov. 20, 2020 /PRNewswire/ — Graphic Packaging Holding Company (NYSE: GPK), (the
“Company” or “Graphic Packaging”), announced today that it has published its 2019 Environmental, Social and Governance (ESG) Report. With this report, the Company has provided additional disclosures using the Sustainability Accounting Standards Board (SASB) reporting framework and has committed to a broader set of environmental, social and governance initiatives.

“Our sustainability reporting continues to exhibit transparency on topics that matter most to investors, customers, employees and other stakeholders,” said Michael Doss, President and Chief Executive Officer. “Customers, suppliers, investors, employees and the communities where Graphic Packaging conducts business have helped shape the Company’s sustainability vision. We are pleased to disclose the significant progress we have made and our resolve for continued improvement on topics that are most impactful and important to these stakeholders.”

Graphic Packaging is working diligently toward meeting its Vision 2025 sustainability goals, and accomplished early achievement of two goals in 2019:

• 100 percent of global folding carton/cup manufacturing facilities are now engaged in a waste diversion program
• 100 percent of global folding carton/cup manufacturing facilities and paperboard mills comply with Graphic Packaging’s forest and fiber certification requirements

Other notable highlights of the 2019 report including ongoing initiatives are as follows:

Environmental
Two products that the Company has introduced, KeelClip^TM and PaperSeal^®, have made dramatic strides for customers with recyclability and sustainability advantages. The 2019 report covers recent product innovations that answer consumers’ expectations for sustainable products and packaging. The Company’s transformational $600 million investment in the new world-class coated recycled board (CRB) machine will have a positive environmental effect by reducing greenhouse gases (GHG), water usage and purchased energy. The report describes the Company’s ongoing investments in its infrastructure and its commitment to operating responsibly. Finally, recognizing the importance of assessing the risk that climate change poses to the business and operations, the Company recently underwent a Climate Change Enterprise Risk Assessment by KPMG and completed an inaugural GHG Inventory Mapping and Assurance by an independent third party. Additionally, the 2019 ESG report is also informed by the Task Force on Climate-related Financial Disclosures.

Social
Employees are the single greatest asset at the Company, and a diverse and inclusive environment is critical to achieving its goals and ensuring employee satisfaction. The 2019 report includes diversity metrics at different levels of the business and highlights how the Board of Directors is closely involved in efforts to accelerate progress. The Company also believes in advocating for positive change in the world, encouraging employees’ participation in community outreach and several philanthropies globally.

Governance
The Board amended in 2019 the Charter of the Nominating and Corporate Governance Committee to formally assign principal oversight of sustainability reporting and practices to the Committee. The Committee now considers current and emerging social and environmental trends and other public policy issues that may affect the business operations or its stakeholders.

ESG Hub and Reporting Frameworks
To enhance communication of Graphic Packaging’s ESG programs and milestones, the Investor section of the Company’s website http://www.graphicpkg.com now includes an ESG page. In addition to the SASB framework, the 2019 report is aligned with GRI Core standards. A copy of the ESG report, key highlights from the year as well as progress on goals, GRI/SASB indices, among other helpful information can be accessed here. Graphic Packaging strives to achieve best-in-class transparency and the Company will provide updates of progress on goals laid out in Vision 2025, as well as other news and detail on innovation and sustainability advancements at the Company in its annual ESG reports and through updates on the ESG hub.

Forward Looking Statements
Any statements of the Company’s expectations, including but not limited to statements about the new CRB machine and any environmental improvements related thereto, in this press release constitute “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995. Such statements are based on currently available information and are subject to various risks and uncertainties that could cause actual results to differ materially from the Company’s present expectations. Undue reliance should not be placed on such forward-looking statements, as such statements speak only as of the date on which they are made and the Company undertakes no obligation to update such statements, except as required by law. Additional information regarding these and other risks is contained in the Company’s periodic filings with the SEC.

About Graphic Packaging Holding Company
Graphic Packaging Holding Company (NYSE: GPK), headquartered in Atlanta, Georgia, is committed to providing consumer packaging that makes a world of difference. The Company is a leading provider of paper-based packaging solutions for a wide variety of products to food, beverage, foodservice, and other consumer products companies. The Company operates on a global basis, is one of the largest producers of folding cartons and paper-based foodservice products in the United States, and holds leading market positions in coated recycled paperboard, coated unbleached kraft paperboard and solid bleached sulfate paperboard. The Company’s customers include many of the world’s most widely recognized companies and brands. Additional information about Graphic Packaging, its business and its products is available on the Company’s web site at www.graphicpkg.com.

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/graphic-packaging-holding-company-highlights-long-standing-commitment-to-environmental-social-and-governance-initiatives-with-release-of-2019-report-301177910.html

SOURCE Graphic Packaging Holding Company